134 related articles for article (PubMed ID: 38214923)
1. Alternative schedule of temozolomide/capecitabine in neuroendocrine neoplasms.
Melhorn P; Mazal P; Wolff L; Popov P; Kretschmer-Chott E; Haug A; Mayerhoefer ME; Raderer M; Kiesewetter B
Endocr Relat Cancer; 2024 Mar; 31(3):. PubMed ID: 38214923
[TBL] [Abstract][Full Text] [Related]
2. Capecitabine and temozolomide for metastatic intermediate to high-grade pancreatic neuroendocrine neoplasm: a single center experience.
Douangprachanh S; Joo HJ; Park HM; Han N; Jang HY; Koh YH; Kim TH; Han SS; Park SJ; Lee WJ; Woo SM; Chun JW
Korean J Intern Med; 2022 Nov; 37(6):1216-1222. PubMed ID: 36375489
[TBL] [Abstract][Full Text] [Related]
3. Capecitabine and Temozolomide in Advanced Lung Neuroendocrine Neoplasms.
Al-Toubah T; Morse B; Strosberg J
Oncologist; 2020 Jan; 25(1):e48-e52. PubMed ID: 31455747
[TBL] [Abstract][Full Text] [Related]
4. Activity and Safety of Standard and Prolonged Capecitabine/Temozolomide Administration in Patients with Advanced Neuroendocrine Neoplasms.
Chatzellis E; Angelousi A; Daskalakis K; Tsoli M; Alexandraki KI; Wachuła E; Meirovitz A; Maimon O; Grozinsky-Glasberg S; Gross D; Kos-Kudła B; Koumarianou A; Kaltsas G
Neuroendocrinology; 2019; 109(4):333-345. PubMed ID: 31167197
[TBL] [Abstract][Full Text] [Related]
5. A retrospective study of capecitabine/temozolomide (CAPTEM) regimen in the treatment of metastatic pancreatic neuroendocrine tumors (pNETs) after failing previous therapy.
Saif MW; Kaley K; Brennan M; Garcon MC; Rodriguez G; Rodriguez T
JOP; 2013 Sep; 14(5):498-501. PubMed ID: 24018594
[TBL] [Abstract][Full Text] [Related]
6. The Role of Capecitabine/Temozolomide in Metastatic Neuroendocrine Tumors.
Ramirez RA; Beyer DT; Chauhan A; Boudreaux JP; Wang YZ; Woltering EA
Oncologist; 2016 Jun; 21(6):671-5. PubMed ID: 27226359
[TBL] [Abstract][Full Text] [Related]
7. The optimal duration of capecitabine plus temozolomide in patients with well-differentiated pancreatic NETs with or without maintenance therapy.
Gao H; Dong J; Zhang W; Xu H; Ye L; Li H; Wang W; Liu L; Yu X
J Neuroendocrinol; 2022 Jun; 34(6):e13112. PubMed ID: 35380016
[TBL] [Abstract][Full Text] [Related]
8. Temozolomide Alone or Combined with Capecitabine for the Treatment of Metastatic Neuroendocrine Neoplasia: A "Real-World" Data Analysis.
Bongiovanni A; Liverani C; Foca F; Fausti V; Di Menna G; Mercatali L; De Vita A; Riva N; Calpona S; Miserocchi G; Spadazzi C; Cocchi C; Ibrahim T
Neuroendocrinology; 2021; 111(9):895-906. PubMed ID: 33221806
[TBL] [Abstract][Full Text] [Related]
9. Temozolomide in Grade 3 Gastroenteropancreatic Neuroendocrine Neoplasms: A Multicenter Retrospective Review.
Chan DL; Bergsland EK; Chan JA; Gadgil R; Halfdanarson TR; Hornbacker K; Kelly V; Kunz PL; McGarrah PW; Raj NP; Reidy DL; Thawer A; Whitman J; Wu L; Becker C; Singh S
Oncologist; 2021 Nov; 26(11):950-955. PubMed ID: 34342086
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and Toxicity Analysis of Capecitabine and Temozolomide in Neuroendocrine Neoplasms.
Al-Toubah T; Pelle E; Valone T; Haider M; Strosberg JR
J Natl Compr Canc Netw; 2021 Aug; 20(1):29-36. PubMed ID: 34433130
[TBL] [Abstract][Full Text] [Related]
11. Capecitabine and Temozolomide as a Promising Therapy for Advanced Thymic Atypical Carcinoid.
Wang X; Li Y; Duan J; Chen Y; Yuan B; Qi Z; Tan H
Oncologist; 2019 Jun; 24(6):798-802. PubMed ID: 30413666
[TBL] [Abstract][Full Text] [Related]
12. Sequential Capecitabine/Temozolomide and Sunitinib Treatment in Patients With Metastatic Well-Differentiated Grade 1/Grade 2 Pancreatic Neuroendocrine Tumors.
Gao H; Dong J; Zhang W; Xu H; Ye L; Li H; Ni Q; Wang W; Liu L
Endocr Pract; 2022 Mar; 28(3):292-297. PubMed ID: 34454077
[TBL] [Abstract][Full Text] [Related]
13. Integrated Capecitabine-Temozolomide with Radioembolization for Liver-Dominant G2 NETs: Long-Term Outcomes of a Single-Institution Retrospective Study.
Soulen MC; Teitelbaum UR; Mick R; Eads J; Mondschein JI; Dagli M; van Houten D; Damjanov N; Schneider C; Cengel K; Metz DC
Cardiovasc Intervent Radiol; 2024 Jan; 47(1):60-68. PubMed ID: 38057498
[TBL] [Abstract][Full Text] [Related]
14. Capecitabine and Temozolomide in Patients with Advanced Pulmonary Carcinoid Tumours.
Papaxoinis G; Kordatou Z; McCallum L; Nasralla M; Lamarca A; Backen A; Nonaka D; Mansoor W
Neuroendocrinology; 2020; 110(5):413-421. PubMed ID: 31437838
[TBL] [Abstract][Full Text] [Related]
15. Capecitabine and temozolomide combination for treatment of high-grade, well-differentiated neuroendocrine tumour and poorly-differentiated neuroendocrine carcinoma - retrospective analysis.
Rogowski W; Wachuła E; Gorzelak A; Lebiedzińska A; Sulżyc-Bielicka V; Iżycka-Świeszewska E; Żołnierek J; Kos-Kudła B
Endokrynol Pol; 2019; 70(4):313-317. PubMed ID: 30843182
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of Capecitabine and Temozolomide Regimen in Neuroendocrine Tumors: Data From the Turkish Oncology Group.
Ünal Ç; Azizy A; Karabulut S; Taştekin D; Akyıldız A; Yaşar S; Yalçın Ş; Çoban E; Evrensel T; Kalkan Z; Oruç Z; Derin S; Turna ZH; Bayram D; Köş FT; Şendur MAN; Sever N; Ercelep Ö; Seyyar M; Kefeli U; Uygun K; Özçelik M; Ön S; Şanlı UA; Canaslan K; Ünek İT; Yücel KB; Özdemir N; Yazıcı O; Güzel HG; Salim DK; Göksu SS; Tatlı AM; Ordu Ç; Selvi O; Sakin A; Büyükbayram ME; Dursun B; Ürün Y; Arak H; Ağdaş G; Uğraklı M; Hendem E; Eryılmaz MK; Bilgin B; Topçu A; Şimşek M; Büyükşimşek M; Akay B; Erdal GŞ; Karataş F; Alan Ö; Çağlayan M; Kahvecioğlu FA; Demirci A; Paksoy N; Çetin B; Gümüş M; Ak N; Aydınalp Y; Paydaş S; Güven DC; Kılıçkap S; Sağlam S
Oncologist; 2023 Oct; 28(10):875-884. PubMed ID: 37676712
[TBL] [Abstract][Full Text] [Related]
17. Capecitabine-Temozolomide in Advanced Grade 2 and Grade 3 Neuroendocrine Neoplasms: Benefits of Chemotherapy in Neuroendocrine Neoplasms with Significant 18FDG Uptake.
Ostwal V; Basu S; Bhargava P; Shah M; Parghane RV; Srinivas S; Chaudhari V; Bhandare MS; Shrikhande SV; Ramaswamy A
Neuroendocrinology; 2021; 111(10):998-1004. PubMed ID: 33017827
[TBL] [Abstract][Full Text] [Related]
18. Utility of clinical and MR imaging parameters for prediction and monitoring of response to capecitabine and temozolomide (CAPTEM) therapy in patients with liver metastases of neuroendocrine tumors.
Ingenerf M; Auernhammer C; Lorbeer R; Winkelmann M; Mansournia S; Mansour N; Hesse N; Heinrich K; Ricke J; Berger F; Schmid-Tannwald C
Radiol Oncol; 2024 Jun; 58(2):196-205. PubMed ID: 38613843
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of Capecitabine and Temozolomide in Small Bowel (Midgut) Neuroendocrine Tumors.
Al-Toubah T; Morse B; Strosberg J
Curr Oncol; 2022 Jan; 29(2):510-515. PubMed ID: 35200546
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of FOLFOX in Patients with Aggressive Pancreatic Neuroendocrine Tumors After Prior Capecitabine/Temozolomide.
Al-Toubah T; Morse B; Pelle E; Strosberg J
Oncologist; 2021 Feb; 26(2):115-119. PubMed ID: 33225478
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]